Capital Research & Management Co has recently announced that it has increased stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.98%. After grabbing 81.72 million shares, the institutional investor is now in possession of 0.79 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 6.56% having worth around $6.26 billion. Moreover, BlackRock Fund Advisors increased its share by 0.29 million to have a control over 81.32 million shares. And Capital Research & Management Co raised its holdings to 14039.0 shares by acquiring 57.91 million shares or 4.65% of the stake.
Gilead Sciences, Inc. (GILD) concluded trading on 12/27/23 at a closing price of $80.37, with 3.54 million shares of worth about $284.6 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 5.50% during that period and on Wednesday the price saw a gain of about 0.53%. Currently the company’s common shares owned by public are about 1.25B shares, out of which, 1.25B shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 29 analysts are covering the GILD stock and their offered price forecasts bring an average price target of $89.25. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $116.00 and could fall to a lowest price of $69.00. The stock’s current price level is 9.95% above of average price target set by the analysts, while a rise to estimated low would result in loss of -16.48% for the stock. However, touching the estimated high of $116.00 would mean a gain of 30.72% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 86 times over the past 12 months. They bought 586,538 shares in 49 of the transactions. In 37 selling transactions, insiders dumped 214,957 shares.
Vanguard Total Stock Market ETF, American Funds Income Fund of Ame, and Vanguard 500 Index Fund are the top 3 mutual funds which are holding stakes in Gilead Sciences, Inc. Vanguard Total Stock Market ETF is currently holding 39.05 million shares of worth totaling $2.99 billion. The company recently came buying 47245.0 shares which brought its stake up to 3.13% of the company’s outstanding shares. American Funds Income Fund of Ame bought 0.7 million shares, after which its hold over company’s outstanding shares expand to 2.76%, leaving 34.44 million shares with the mutual fund that have a worth of about $2.64 billion. Vanguard 500 Index Fund, after buying 30.09 million shares, have now control over 2.42% of the stake in the company. It holds 0.15 million shares of worth $2.3 billion.
Gilead Sciences, Inc. (NASDAQ: GILD) started trading at $80.11, above $0.16 from concluding price of the previous day. However, the stock later moved at a day high price of 80.75, or with a gain of 0.53%. Stock saw a price change of 1.11% in past 5 days and over the past one month there was a price change of 7.27%. Year-to-date (YTD), GILD shares are showing a performance of -6.38% which decreased to -5.17% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $72.87 but also hit the highest price of $88.29 during that period. The average intraday trading volume for Gilead Sciences, Inc. shares is 6.19 million. The stock is currently trading 1.73% above its 20-day simple moving average (SMA20), while that difference is up 2.88% for SMA50 and it goes to 2.72% higher than SMA200.
Capital Research & Management Co acquired 81.72 million shares of Gilead Sciences, Inc. having value of about $6.26 billion. Data submitted at the U.S SEC by Capital Research & Management Co revealed that the firm now holds 0.79 million shares in the company valued at close to $63658746.27, or have control over 0.98% stake in the company. Gilead Sciences, Inc. (NASDAQ: GILD) currently have 1.25B outstanding shares and institutions hold larger chunk of about 85.17% of that. Holding of mutual funds in the company is about 30.35% while other institutional holders and individual stake holders have control over 55.80% and 1.33% of the stake respectively.
The stock has a current market capitalization of $100.14B and its 3Y-monthly beta is at 0.25. PE ratio of stock for trailing 12 months is 17.23, while it has posted earnings per share of $4.66 in the same period. Its PEG reads 4.18 and has Quick Ratio of 1.20 while making debt-to-equity ratio of 1.12. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for GILD, volatility over the week remained 1.17% while standing at 1.61% over the month.
Analysts are in expectations that Gilead Sciences, Inc. (GILD) stock would likely to be making an EPS of $1.78 in the current quarter, while forecast for next quarter EPS is $1.8 and it is $7.28 for next year. For the current quarter EPS, analysts have given the company a lowest target $1.64 which is $2.04 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $1.67 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -6.62% while it is estimated to increase by 7.58% in next year. EPS is likely to grow at an annualized rate of 4.12% for next 5-years, compared to annual growth of 0.73% made by the stock over the past 5-years.
Analysts at 29 brokerage firms have issued recommendations for the Gilead Sciences, Inc. (GILD)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.21. Out of those 29 Wall Street analysts, 12 recommended a “Buy” rating, while 15 were in favor recommending the stock as a “Hold” and 1 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Deutsche Bank on November 09, 2023 offering a Hold rating for the stock and assigned a target price of $75 to it.
